Associated Papers
Multimodal scanning of genetic variants with base and prime editing.
Belli O et al.
Nature Biotechnology, 2025
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Pancreatic Cancer-Related Mutational Burden Is Not Increased in a Patient Cohort With Clinically Severe Chronic Pancreatitis.
Cowan RW et al.
Clinical and Translational Gastroenterology, 2021
34797250 (PubMed )
Supplement: ct9-12-e00431-s006.xlsx › SDC6
Landscape of drug-resistance mutations in kinase regulatory hotspots.
Kim P et al.
Briefings in Bioinformatics, 2021
An unbiased in vitro screen for activating epidermal growth factor receptor mutations.
Chakroborty D et al.
The Journal of Biological Chemistry, 2019
Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics.
Presneau N et al.
The Journal of Pathology. Clinical Research, 2015
27499898 (PubMed )
Supplement: CJP2-1-113-s004.xlsx › Sheet1
Expression of receptor tyrosine kinases in esophageal carcinosarcoma.
Sano A et al.
Oncology Reports, 2013
Activation of tyrosine kinases by mutation of the gatekeeper threonine.
Azam M et al.
Nature Structural & Molecular Biology, 2008
Select a paper to view details